A few decades ago, the pharmaceutical industry began to undergo a transformation. Previously, research and development in the industry had been predominantly focused on small molecule synthetics and was predominantly conducted by internal R&D groups within the major companies. This model came under pressure as easier targets were addressed, patents on early blockbusters began expiring, and it became clear that while small molecules were effective against their intended targets, they also often had
Share to